Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Glutamate

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    104 result(s) found for: Glutamate. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2017-002636-16 Sponsor Protocol Number: VUMC-ANW-MS-GG-062017 Start Date*: 2017-10-09
    Sponsor Name:VU University medical center Amsterdam
    Full Title: Cognitive impairment and functional reorganization in multiple sclerosis: The role of GABA and glutamate
    Medical condition: Multiple Sclerosis (MS). And specifically cognitive problems in MS.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003123-22 Sponsor Protocol Number: JCS-CBG-2014-01 Start Date*: 2015-01-02
    Sponsor Name:José Castillo Sanchez
    Full Title: "Randomized clinical trial with two parallel groups, double-blind, placebo-controlled trial to investigate whether administration of CBG000592 (riboflavin/vitamin B2) in patients with acute ischemi...
    Medical condition: Acute ischemic stroke
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002011-61 Sponsor Protocol Number: 77267 Start Date*: 2021-08-13
    Sponsor Name:Academisch ziekenhuis Maastricht
    Full Title: The glutamate/GABA balance as novel therapeutic target for psychotic and cognitive symptoms in 22q11.2 deletion syndrome
    Medical condition: 22q11.2 deletion syndrome
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023878-40 Sponsor Protocol Number: 2.3 Start Date*: 2011-12-22
    Sponsor Name:Medical University Vienna
    Full Title: Influence of intra-arterial cerebral Papaverine Hydrochloride on cerebral glucose, lactate, pyruvate, glycerol, and glutamate concentrations, cerebral oxygenation, angiographic vasospasm, delayed s...
    Medical condition: To demonstrate the influence of intra-arterial cerebral Papaverine Hydrochloride on cerebral glucose, lactate, pyruvate, glycerol, and glutamate concentrations and cerebral oxygenation in patients ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-023996-25 Sponsor Protocol Number: 26081985 Start Date*: 2010-12-21
    Sponsor Name:
    Full Title: The effect of fluoxetine and 5-HT4 serotonin receptor agonists on cerebral axonal energy metabolism and glutamate levels in multiple sclerosis.
    Medical condition: Multiple sclerosis (both relapsing remitting and progressive forms)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-000746-32 Sponsor Protocol Number: 5-HT_CFM Start Date*: 2008-04-23
    Sponsor Name:Karolinska Institutet
    Full Title: Validation of experimental pain models as translational for craniofacial myalgia with respect to the influence of 5-HT, glutamate, cortisol and estradiol level
    Medical condition: Patients with craniomandibular myalgia (CM), i.e. with pain in the masster muscle and a diagnosis of myofascial pain according to the RDC/TMD criteria, and healthy subjects of both sexes, over 18 y...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2011-006241-15 Sponsor Protocol Number: GLUTAMICS2 Start Date*: 2012-02-15
    Sponsor Name:Linköping University Hospital
    Full Title: GLUTAmate for Metabolic Intervention in Coronary Surgery II
    Medical condition: Angina CCS class IV treated with coronary artery bypass surgery Coronary artery disease with moderate to severe left ventricular dysfunction treated with coronary artery bypass surgery
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10068176 Coronary artery bypass graft LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003643-23 Sponsor Protocol Number: CRO-06-76 - AB/GAD/21 Start Date*: 2006-06-14
    Sponsor Name:Abiogen Pharma S.p.A.
    Full Title: Efficacy and tolerability study of a novel CNS drug ABIO 08/01 administered for 8 weeks to patients with generalised anxiety disorders
    Medical condition: generalised anxiety disorder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10017571 GAD LLT
    Population Age: Adults Gender: Male
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-001673-15 Sponsor Protocol Number: 12473A Start Date*: 2008-09-18
    Sponsor Name:H. Lundbeck A/S
    Full Title: A double-blind, randomised, placebo-controlled, multicentre, relapse-prevention study with Lu AA21004 in patients with Generalised Anxiety Disorder (GAD)
    Medical condition: Generalised Anxiety Disorder (GAD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10017571 GAD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FR (Completed) FI (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2008-002578-36 Sponsor Protocol Number: 2008/0817 Start Date*: 2008-09-10
    Sponsor Name:CHRU de LILLE
    Full Title: Etude d’efficacité et d’acceptabilité d’un traitement cholinergique dans l’apathie parkinsonienne “Cholinergic treatment in Parkinsonian Apathy: ChoPA - I”
    Medical condition: Parkinsonian Apathy without dementia and depression in spite of dopaminergic treatment
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-000579-40 Sponsor Protocol Number: D1443L00002 Start Date*: 2007-10-10
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: Effects of atypical versus typical neuroleptics on motivation, hedonia, and social cognition in patients with schizophrenia – an fMRI study
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039626 Schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-000526-23 Sponsor Protocol Number: A6181049 Start Date*: 2005-08-30
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 1 STUDY OF SU011248 IN COMBINATION WITH FOLFIRI (IRINOTECAN, 5-FLUOROURACIL AND LEUCOVORIN) IN PATIENTS WITH METASTATIC COLORECTAL CANCER
    Medical condition: Metastatic colorectal cancer.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-000240-26 Sponsor Protocol Number: CBD_ADD_IN Start Date*: 2013-10-29
    Sponsor Name:King's College London [...]
    1. King's College London
    2. South London and Maudsley NHS Foundation Trust
    Full Title: Cannabidiol as an add-on therapy in treatment-refractory psychotic disorders
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    16.1 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000791-42 Sponsor Protocol Number: JVM-GLU-12 Start Date*: 2012-07-26
    Sponsor Name:FUNDACION INVESTIGACION BIOMEDICA HOSPITAL UNIVERSITARIO LA PRINCESA
    Full Title: OPEN, RANDOMIZED AND CONTROLLED STUDY OF SAFETY AND VIABILITY, TO EVALUATE THE NEUROPROTECTIVE EFFECT OF PLASMA GLUTAMATE DIALYSIS IN ACUTE ISCHEMIC STROKE.
    Medical condition: BRAIN ISCHEMIC STROKE IN ACUTE PHASE
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-003089-16 Sponsor Protocol Number: AGO-OVAR2.11 Start Date*: 2007-08-31
    Sponsor Name:AGO Research GmbH
    Full Title: Phase II trial in platinum-refractory ovarian cancer: a randomized multicenter trial with SU11248 to evaluate dosage, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine k...
    Medical condition: Platinum refractory or resistant ovarian cancer, primary cancer of the peritoneum or fallopian tube (defined as stable (SD) or progressive disease (PD) during platinum containing chemotherapy, or ...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004587-23 Sponsor Protocol Number: UZL/MBC SUBE0501 Start Date*: 2005-12-23
    Sponsor Name:UZ Leuven
    Full Title: A belgian multicenter phase II randomized trial in her2 negative metastatic breast cancer evaluating consolidation antiangiogenic therapy with SU11248 after response to taxane chemotherapy induction
    Medical condition: Patients must meet all of the following inclusion criteria in order to be eligible for participation in this study: • Patients with metastatic breast cancer, histologically proven • Patients receiv...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-001863-35 Sponsor Protocol Number: THAM Start Date*: 2016-06-21
    Sponsor Name:Universitätsklinik für Klinische Pharmakologie, Medizinische Universität Wien
    Full Title: Effects of Tromethamine on Cerebral Oxygenation and Metabolism in Patients Suffering Intractable Intracranial Hypertension – an exploratory study.
    Medical condition: Critically ill patients (SAH, ICB, AVM bleedings, malignant MCA infarcts) under sedation and mechanical ventilation in need of multimodality monitoring, including brain tissue oxygen monitoring and...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003910-26 Sponsor Protocol Number: 01/2015 Start Date*: 2017-12-11
    Sponsor Name:Núcleo de Estudos de Hipertensão da Beira Interior
    Full Title: Fase II, unicenter, open, randomized trial to evaluate the response of Th17 and T regulatory lymphocytes to 24 weeks supplementation with cholecalciferol in patients with arterial hypertension, obe...
    Medical condition: Obesity associated arterial hypertension Metabolic syndrome associated arterial hypertension
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002320-25 Sponsor Protocol Number: UC_0106/1712 Start Date*: 2018-07-03
    Sponsor Name:UNICANCER
    Full Title: Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: A phase II randomized study by the UNICANCER with cooperation of AFSOS.
    Medical condition: Colorectal cancer stage II/III with adjuvant oxaliplatin-based chemotherapy (simplified FOLFOX4)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-006244-73 Sponsor Protocol Number: EC11-387 Start Date*: 2012-05-29
    Sponsor Name:Instituto Aragonés de Ciencias de la Salud
    Full Title: Evaluation of the efficacy of memantine in the treatment of fibromyalgia: a double-blind randomized control clinical trial.
    Medical condition: Fibromyalgia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 09:56:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA